Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President and CEO

SVP, Chief Medical Officer

SVP & COO

SVP & General Counsel

SVP & CFO

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of a...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-27	Premium	bought	Premium	Premium	Premium	President and CEO
2023-09-26	Premium	bought	Premium	Premium	Premium	President and CEO
2023-08-23	Premium	acquired	Premium	Premium	Premium	SVP, Chief Medical Officer
2023-08-23	Premium	acquired	Premium	Premium	Premium	SVP & COO
2023-08-23	Premium	acquired	Premium	Premium	Premium	-
2023-08-23	Premium	acquired	Premium	Premium	Premium	-
2023-08-23	Premium	acquired	Premium	Premium	Premium	-
2023-08-23	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-08-23	Premium	acquired	Premium	Premium	Premium	-
2023-04-26	Premium	bought	Premium	Premium	Premium	President and CEO
2023-04-25	Premium	bought	Premium	Premium	Premium	President and CEO
2023-02-28	Premium	sold (taxes)	Premium	Premium	Premium	SVP & COO
2023-02-28	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Medical Officer
2023-02-28	Premium	sold (taxes)	Premium	Premium	Premium	SVP & General Counsel
2023-02-28	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2023-02-22	Premium	acquired	Premium	Premium	Premium	-
2022-07-27	Premium	bought	Premium	Premium	Premium	President and CEO
2022-07-26	Premium	bought	Premium	Premium	Premium	President and CEO
2022-07-26	Premium	bought	Premium	Premium	Premium	SVP & CFO
2022-06-30	Premium	bought	Premium	Premium	Premium	President and CEO
2022-06-29	Premium	bought	Premium	Premium	Premium	President and CEO
2022-06-07	Premium	acquired	Premium	Premium	Premium	-
2022-06-07	Premium	acquired	Premium	Premium	Premium	-
2022-06-07	Premium	acquired	Premium	Premium	Premium	-
2022-06-07	Premium	acquired	Premium	Premium	Premium	-

WINT - Windtree Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for WINT